Table 50

Quantitative syntheses of longer term outcomes data (clinical, serious adverse events and cancer) for omega-3 fatty acid plus statin therapy compared with statin monotherapy

PopulationNumber of trials reporting outcomeNumber of participants in relevant intervention groupsNumber of participants with eventsOdds ratioLower CIUpper CI
All-cause mortality
All trials141,177,1803189405511.080.911.28
All trials 24 weeks or more followup1411186455511.080.911.28
Adequate allocation concealment141,1802188995511.080.911.28
Participants of Asian descent1411186455511.080.911.28
Fatal myocardial infarction
Participants requiring intensive lipid lowering therapy176
Participants with vascular disease – All trials176125410.290.017.39
Participants with vascular disease – All trials 24 weeks or more followup176
All trials141,176218700260.730.341.58
All trials 24 weeks or more followup141,176
Non-fatal myocardial infarction
All trials141
All trials 24 weeks or more followup1411186451450.750.541.03
Unspecified myocardial infarction
All trials1411186451640.760.561.04
All trials 24 weeks or more followup141
Hemorrhagic stroke
All trials141
All trials 24 weeks or more followup141118645881.260.831.91
Ischemic stroke
All trials141
All trials 24 weeks or more followup1411186452380.930.721.21
Unspecified stroke
All trials141
All trials 24 weeks or more followup1411186453280.420.101.87
Serious adverse events
All trials180125454.440.4940.29
Cancer
Cancer1411186454601.110.921.34

Abbreviations: CI 95% confidence interval

From: 3, Results

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.